Exact Sciences (EXAS) Misses Q3 EPS by 1c, Lowers Guidance
Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $709 million versus the consensus estimate of $716.8 million.
GUIDANCE:
Exact Sciences sees FY2024 revenue of $2.73-2.75 billion, versus the consensus of $2.83 billion.
The Company has updated its full-year 2024 revenue and adjusted EBITDA guidance:
| Prior guidance |
| November 5 update |
Total revenue | $2.810 - $2.850 billion |
| $2.730 - $2.750 billion |
Screening | $2.155 - $2.175 billion |
| $2.080 - $2.095 billion |
Precision Oncology | $655 - $675 million |
| $650 - $655 million |
Adjusted EBITDA | $335 - $355 million |
| $310 - $320 million |
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.